Celcuity LLC (CELC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.15B
Last updated: Nov 17, 2026 at 11:05 AM ET
Celcuity LLC (CELC) Earnings: Report Dates and Results
Celcuity LLC (CELC) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Celcuity LLC reported EPS of -$1.33, above the -$1.47 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CELC has an expected report date of Mar 23, 2027.
CELC Earnings Call
The latest CELC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, CELC beat 19, missed 17 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2021, when EPS landed 214.29% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.33 | -$1.47 | -$1.60 - -$1.47 | +9.52% | Beat | N/A | 2 | 0 up, 2 down | Nov 5, 2026 |
| Jun 30, 2026 | -$1.44 | -$1.08 | -$1.25 - -$0.91 | -33.33% | Miss | N/A | 2 | 0 up, 1 down | Aug 13, 2026 |
| Mar 31, 2026 | -$0.86 | -$0.89 | -$0.89 - -$0.89 | +3.37% | Beat | N/A | 1 | 1 up, 0 down | May 14, 2026 |
| Dec 31, 2025 | -$0.73 | -$1.05 | N/A | +30.48% | Beat | N/A | 3 | 0 up, 2 down | Mar 25, 2026 |
| Sep 30, 2025 | -$0.78 | -$0.96 | -$0.97 - -$0.94 | +18.75% | Beat | N/A | 3 | 0 up, 2 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.93 | -$0.84 | -$0.86 - -$0.83 | -10.71% | Miss | N/A | 2 | 0 up, 1 down | Aug 14, 2025 |
| Mar 31, 2025 | -$0.81 | -$0.86 | -$0.86 - -$0.86 | +5.81% | Beat | N/A | 1 | 0 up, 1 down | May 14, 2025 |
| Dec 31, 2024 | -$0.75 | -$0.67 | -$0.67 - -$0.67 | -11.94% | Miss | N/A | 1 | 1 up, 0 down | Mar 31, 2025 |
| Sep 30, 2024 | -$0.65 | -$0.70 | -$0.70 - -$0.70 | +7.14% | Beat | N/A | 1 | 0 up, 1 down | Nov 14, 2024 |
| Jun 30, 2024 | -$0.58 | -$0.55 | N/A | -5.45% | Miss | N/A | 7 | 0 up, 0 down | Aug 14, 2024 |
| Mar 31, 2024 | -$0.64 | -$0.71 | -$0.78 - -$0.59 | +9.86% | Beat | N/A | 6 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.61 | -$0.75 | -$0.93 - -$0.51 | +18.67% | Beat | N/A | 6 | 0 up, 0 down | Mar 27, 2024 |
| Sep 30, 2023 | -$0.78 | -$0.53 | N/A | -47.17% | Miss | N/A | 4 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$0.58 | -$0.46 | N/A | -26.09% | Miss | N/A | 4 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.47 | -$0.43 | -$0.69 - -$0.33 | -9.30% | Miss | N/A | 4 | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$0.69 | -$0.44 | -$0.73 - -$0.33 | -56.82% | Miss | N/A | 4 | 0 up, 0 down | Mar 23, 2023 |
| Sep 30, 2022 | -$0.75 | -$0.60 | -$0.68 - -$0.32 | -25.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 10, 2022 |
| Jun 30, 2022 | -$0.55 | -$0.48 | -$0.59 - -$0.34 | -14.58% | Miss | N/A | 4 | 0 up, 0 down | Aug 11, 2022 |
| Mar 31, 2022 | -$0.53 | -$0.51 | -$0.56 - -$0.45 | -3.92% | Miss | N/A | 3 | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$0.37 | -$0.35 | -$0.41 - -$0.35 | -5.71% | Miss | N/A | 4 | N/A | Mar 23, 2022 |
| Sep 30, 2021 | -$0.35 | -$0.24 | N/A | -45.83% | Miss | N/A | 5 | N/A | Nov 8, 2021 |
| Jun 30, 2021 | -$0.66 | -$0.21 | N/A | -214.29% | Miss | N/A | 3 | N/A | Aug 9, 2021 |
| Mar 31, 2021 | -$0.21 | -$0.20 | -$0.20 - -$0.20 | -5.00% | Miss | N/A | 1 | N/A | May 10, 2021 |
| Dec 31, 2020 | -$0.21 | -$0.22 | -$0.22 - -$0.22 | +4.55% | Beat | N/A | 1 | N/A | Feb 16, 2021 |
| Sep 30, 2020 | -$0.24 | -$0.23 | -$0.23 - -$0.23 | -4.35% | Miss | N/A | 1 | N/A | Nov 9, 2020 |
| Jun 30, 2020 | -$0.17 | -$0.18 | -$0.18 - -$0.18 | +5.56% | Beat | N/A | 1 | N/A | Aug 10, 2020 |
| Mar 31, 2020 | -$0.17 | -$0.17 | -$0.17 - -$0.17 | 0.00% | In line | N/A | 1 | N/A | May 7, 2020 |
| Dec 31, 2019 | -$0.14 | -$0.18 | -$0.19 - -$0.18 | +22.22% | Beat | N/A | 2 | N/A | Mar 12, 2020 |
| Sep 30, 2019 | -$0.16 | -$0.17 | -$0.18 - -$0.17 | +5.88% | Beat | N/A | 2 | N/A | Nov 7, 2019 |
| Jun 30, 2019 | -$0.15 | -$0.18 | -$0.20 - -$0.18 | +16.67% | Beat | N/A | 2 | N/A | Aug 8, 2019 |
| Mar 31, 2019 | -$0.16 | -$0.20 | N/A | +20.00% | Beat | N/A | 2 | N/A | May 7, 2019 |
| Dec 31, 2018 | -$0.15 | -$0.18 | -$0.20 - -$0.17 | +16.67% | Beat | N/A | 2 | N/A | Feb 26, 2019 |
| Sep 30, 2018 | -$0.15 | -$0.18 | N/A | +16.67% | Beat | N/A | N/A | N/A | Nov 13, 2018 |
| Jun 30, 2018 | -$0.15 | -$0.17 | -$0.17 - -$0.17 | +11.76% | Beat | N/A | 1 | N/A | Aug 9, 2018 |
| Mar 31, 2018 | -$0.16 | -$0.19 | -$0.19 - -$0.19 | +15.79% | Beat | N/A | 1 | N/A | May 14, 2018 |
| Dec 31, 2017 | -$0.14 | -$0.15 | -$0.15 - -$0.15 | +6.67% | Beat | N/A | 1 | N/A | Mar 15, 2018 |
| Sep 30, 2017 | -$0.20 | -$0.19 | N/A | -5.26% | Miss | N/A | N/A | N/A | Nov 13, 2017 |
| Jun 30, 2017 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 20, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.25, after -$2.62 the year before. It was -$0.45 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.25 | N/A |
| Dec 31, 2024 | -$2.62 | N/A |
| Dec 31, 2023 | -$2.44 | N/A |
| Dec 31, 2022 | -$2.52 | N/A |
| Dec 31, 2021 | -$1.59 | N/A |
| Dec 31, 2020 | -$0.79 | N/A |
| Dec 31, 2019 | -$0.61 | N/A |
| Dec 31, 2018 | -$0.61 | N/A |
| Dec 31, 2017 | -$0.45 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,500 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,533 | 15 | |
| 2026Q2 | Jun 30, 2026 | 5,224 | 14 | |
| 2026Q1 | Mar 31, 2026 | 5,633 | 15 | |
| 2025Q4 | Dec 31, 2025 | 5,213 | 13 | |
| 2025Q3 | Sep 30, 2025 | 3,707 | 11 | |
| 2025Q2 | Jun 30, 2025 | 4,477 | 10 | |
| 2025Q1 | Mar 31, 2025 | 3,705 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,547 | 10 |
2026Q3 Earnings Call
Opening remarks
Jodi Sievers Investor Relations Thank you, Marissa, and good afternoon, everyone. Thank you for joining us to review Celcuity's third quarter 2026 financial results and business update. Earlier today, Celcuity, Inc. released financial results for the quarter ended September 30, 2026. The press release can be found on the Investors section of Celcuity's website. Joining me on the call today are Brian F. Sullivan, Celcuity's Chief Executive Officer and co-founder; Vicky Hahne, our Chief Financial Officer; as well as Igor, our Chief Medical Officer, and Eldon C. Mayer, our Chief Commercial Officer, who will both be available for questions during Q&A. Before we begin, I would like to remind listeners that our comments today include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. On this call, we also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non-GAAP financial measures to GAAP measures in today's press release. With that, I would like to turn the call over to Brian F. Sullivan, CEO of Celcuity.
Brian F. Sullivan CEO Thank you, Jodi, and good afternoon, everyone. Thank you for joining our third quarter 2026 operating and financial update conference call. 2026 has been a transformative year for Celcuity as we transition to a commercial-stage company. Revtopik is now available to U.S. physicians to prescribe for use in combination with fulvestrant, with or without palbociclib, for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The unprecedented efficacy results and favorable safety profile reported from the PIK3CA wild-type cohort of the VIKTORIA-1 study provide physicians with a compelling rationale to utilize a gedatolisib regimen to address a significant unmet need for the tens of thousands of patients affected each year by advanced breast cancer. We are pleased to report and provide our first update on the results of the foundational work our commercial and medical teams have been performing for the past two years to prepare for the commercial launch of Revtopik.
Frequently Asked Questions About CELC
When is Celcuity LLC's next earnings date?
Celcuity LLC's next earnings report is expected for Mar 23, 2027.
Did CELC beat earnings estimates last quarter?
Yes. Celcuity LLC reported EPS of -$1.33 for the quarter ended Sep 30, 2026, above the -$1.47 estimate, a 9.52% surprise.
What EPS do analysts expect from CELC next quarter?
The consensus EPS estimate for Celcuity LLC for the quarter ending Dec 31, 2026 is -$1.41 from 14 analysts, with estimates from -$1.86 to -$1.12.
How often does CELC beat earnings estimates?
Celcuity LLC beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.49%.
CELC pages: Overview, Earnings, Forecast, Financials, Competitors